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Abstract Gpl30 is the signal transducing subunit of the inter- 
leukin-6 receptor. Signaling is initiated by the complex formation 
of gpl30 with IL-6 bound to the IL-6 receptor (IL-6R). We have 
subdivided the extracellular domain of gpl30 in two parts and 
expressed the mutant proteins as soluble IgG fusion proteins in 
COS-7 cells. By studying the formation of the ternary complex 
we show that the membrane distal half of gpl30 which contains 
a cytokine receptor domain is responsible for the interaction with 
the IL-6/IL-6R complex. Interestingly this is the same region 
which is believed to be involved in specific recognition of the 
related cytokines LIF, OM, and probably also of CNTF and 
IL-11. 
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1. Introduction 
Recently, IL-6, CNTF, OM, LIF and IL-11 were defined as 
a family of pleiotropic ytokines with overlapping biological 
activities. They share the glycoprotein gpl30 as a common 
component for signal transduction across the cell membrane 
which may explain the functional redundancy of these cytoki- 
nes [1-5]. 
For receptor activation, IL-6, CNTF and IL-11 first bind to 
a specific ~z-receptor subunit. Subsequently his complex associ- 
ates with gpl30 [6-8]. Signal transduction requires either ho- 
modimerization f gpl30 as in the case of IL-6 [9], or heterod- 
imerization with the LIF receptor as in the cases of LIF (after 
it has bound the LIF receptor) and CNTF [10,11]. Gpl30 itself 
shows no measurable affinity to IL-6 [6]. Recently, however, it 
was shown that OM binds directly to gpl30 [12,13] and that, 
at high concentrations, OM can inhibit the IL-6 activities on 
cells that do not respond to OM [13]. This is a first indication 
that an identical domain of the gp130 extracellular domain can 
interact with different cytokines/cytokine-receptor complexes. 
Gpl30 is a ubiquitously expressed 130 kDa glycoprotein 
consisting of an extracellular region of 597 amino acids, a single 
membrane spanning region of 22 and a cytoplasmic domain of 
277 amino acids length [14]. The extracellular part of gp130 is 
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composed of six fibronectin type III modules, the second and 
third of which (amino acids 125 to 320) form a cytokine recep- 
tor domain [15] characterized by four conserved cysteine resi- 
dues and a WSXWS motif [16,17]. 
It has not as yet been determined which site(s) of gpl30 is 
(are) involved in the complex formation with IL-6 and the 
IL-6R. Referring to the related growth hormone/growth 
hormone receptor system the structure of which has been 
solved [18,19] the cytokine receptor domain of gpl30 can be 
predicted to be responsible for this interaction. We have con- 
structed two different deletion mutants of the soluble human 
gp 130 (shgp 130) lacking either the three distal fibronectin type 
III modules including the cytokine receptor domain (amino 
acids 16 to 304) or the three membrane proximal fibronectin 
type III modules (amino acids 302 to 582). By studying the 
formation of the ternary complex between the soluble IL-6 
receptor, IL-6 and these soluble gp 130 deletion mutants we now 
show directly that the membrane distal half of gp130 compris- 
ing the cytokine receptor domain is sufficient for the interaction 
with IL-6 bound to its soluble IL-6 receptor. 
2. Materials and methods 
2.1. Chemicals 
Restriction enzymes EcoRI, XhoI and BstEII were obtained from 
Boehringer Mannheim (Mannheim, Germany) and T7 polymerase - 
quencing kit from Pharmacia (Freiburg, Germany). Tran[35S]label was 
purchased from ICN (Meckenheim, Germany). DMEM was obtained 
from Gibco (Eggenstein, Germany) and FCS from Seromed (Berlin, 
Germany). Human IL-6 cDNA was a gift from Drs. T. Hirano and T. 
Kishimoto (Osaka, Japan). The eukaryotic expression vector 
pSVLgpl30 was generously supplied by Dr. T. Taga (Osaka, Japan), 
the expression plasmid pCDM8-gpl30-IgG1 was a kind gift of Dr. J. 
Liu (Boise, Idaho). The expression vector pSVLgpl30-IgG was gener- 
ated by subcloning the pCDM8-gpl30-IgG1 insert into the vector 
pSVL. The polyclonal rabbit-anti-human IL-6R antiserum was raised 
against apart of the IL-6R extracellular domain [20]. 
2.2. Cell culture 
Simian kidney cells (COS-7) were cultured in DMEM supplemented 
with 10% FCS, 100 mg/1 streptomycin a d 60 mg/1 penicillin. Cells were 
grown at 37°C in a water-saturated atmosphere at5% CO2. 
2.3. Construction of gpl30 deletion mutants and gpl30-IgG1 fusion 
proteins 
The deletion mutants of the transmembrane gp130 were constructed 
using the PCR technique [21]. The mutant gpl30ACR lacks the three 
membrane distal fibronectin type III modules including the cytokine 
receptor domain (nucleotides 112 to 978, amino acids 16 to 304). To 
construct this mutant we used the oligonucleotide 5'-ATCTGGTGC- 
TTTAGA/AACTGGAGATTCAGG-Y (antisense) the first fifteen u- 
cleotides of which are complementary to the gpl30 nucleotides 96 to 
111 upstream of the sequence to be deleted, whereas the last fifteen 
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nucleotides are complementary to the downstream gpl30 nucleotides 
979 to 994. For a first PCR to generate the 5' sequence of the mutant 
we used the expression plasmid pSVLgpl30 as template. As primers we 
employed the described antisense oligonucleotide as well as a pSVL 
sequence primer 5'-GTCTTACTTCTGCTCT-Y (sense) that anneals to 
the pSVL vector upstream of the gpl30 eDNA. A second PCR to 
generate the 3' sequence was carried out with the product received in 
the first PCR as sequence primer and a pSVL reverse sequence primer 
5'-TCTAGTTGTGGTTTG-3' (antisense) complementary to the pSVL 
sequence downstream the gpl30 eDNA. Again, the template was the 
plasmid pSVLgp130. Analogously we proceeded with the construction 
of the deletion mutant gp130AF lacking the three membrane proximal 
fibronectin type III modules (nucleotides 999 to 1812; amino acids 302 
to 582). The gpl30 hybridizing oligonucleotide was 5'-GCACCAAG- 
TTTCTGG/GAATTCACTTTTACT-3' (sense) with the nucleotides 1 
to 15 hybridizing with the nucleotides 983 to 999 upstream and the 
nucleotides 16 to 30 annealing with the nucleotides 1813 to 1828 down- 
stream of the gpl30 sequence to be deleted. The first PCR was per- 
formed with the described oligonucleotide and the pSVL reverse se- 
quence primer as primers and pSVLGP130 as template. For the second 
PCR the PCR product and the pSVL sequence primer were used as 
primers. All PCRs were carried out using 1 pg of the oligonucleotides 
described, 0.5 pg of the pSVL sequence primer or the pSVL reverse 
sequence primer and 1 ktg of template. The PCR reactions were per- 
formed under the following conditions: first denaturation, 60s at 94 ° C, 
annealing, 60 s at 45°C, primer extension, 60 s at 72°C, denaturation, 
45 s at 94°C (35 cycles), last primer extension, 300 s at 72°C. The 
resulting PCR products were digested with the restriction enzymes XhoI 
and BstEII and cloned into the vector pSVLgp 130. The integrity of the 
constructs pSVLgp 130ACR and pSVLgp 130AF was verified by restric- 
tion analysis and by DNA sequencing. 
The soluble human gpl30-IgG1 fusion proteins hgpl30ACR-IgG 
and shgp130AF-IgG, were generated by subcloning the cDNAs encod- 
ing the truncated gpl30 extracellular domains into the vector 
pSVLshgpl30-IgG [22]. The cDNAs were cut out of the vectors 
pSVLgpl30ACR and pSVLgpl30AF via the XhoI and the EcoRI re- 
striction sites. The pSVL EcoRI restriction site of pSVLgp 130-IgG was 
destroyed before. 
2.4. Transfection and metabolic labeling 
107 COS-7 cells were transiently transfected with 30/zg of plasmid 
DNA by electroporation (Gene Pulser, Bio-Rad). The electroporation 
was performed at 960/tF and 230 V. 48 hours after transfection the cells 
were metabolically labeled with [35S]cysteine/methionine for 4 h and 
chased with unlabeled medium over night. Supernatant of the cells were 
collected and cells were lysed in 1% Nonidet P40, 10 mM Tris-HC1, pH 
7.4, 0.4% Na-deoxycholat, 60 mM EDTA, 0.3% SDS, 1% Triton X-100, 
in the presence of the protease inhibitors PMSF (0.2 mM), aprotinine 
(5/2g/ml), leupeptine (1/2g/ml), pepstatin (1 pg/ml). 
2.5. Formation of the ternary complex 
COS-7 cells were transiently transfected with the expression vector 
pCDM8-huIL-6R [23,24] encoding the human IL-6R, and metaboli- 
cally labeled with [35S]cysteine/methionine. The generation of 35S-la- 
beled soluble human IL-6R ([35S]shIL-6R) was induced by the addition 
of 0,1/2M PMA [23,24]. Supernatants of COS-7 cells transiently trans- 
fected with the shgp130-IgG fusion proteins were precipitated with 1.25 
mg/ml protein A-Sepharose via the IgG domain at 4°C for 12 h. Com- 
plex formation was cunducted by adding 250 pl supernatant containing 
[35S]shIL-6R and 200 ng of IL-6 to the protein A-Sepharose bound 
gpl30 proteins to a final volume of 1 ml. After over night incubation 
at 4°C the IL-61[35S]shIL-6R/shgp 130-IgG complexes were sedimented 
by centrifugation at2000 rpm. Ternary complex formation was visual- 
ized by detection of a 55 to 60 kDa protein after SDS-PAGE (10%) and 
fluorography [25,26]. 
3. Results and discussion 
The signal transducer gp 130 is known to have no measurable 
affinity for IL-6 but specifically binds a complex of IL-6 and 
IL-6R [9,14]. This was not only shown for the membrane- 
bound receptor subunits but also for the soluble forms of IL-6R 
and gpl30 which were found in human serum [27,28]. 
A 
gp130 
B 
shgp130-1gG shgp130AF-IgG shgp130ACR-IgG 
Fig. 1. Schematic representation f (A) membrane-bound gpl30 and 
(B) IgG fusion proteins of soluble human gp 130 (shgp 130-IgG) and the 
deletion mutants hgp130AF-IgG and shgp130ACR-IgG there of. The 
cytokine receptor domain is shown in black, the IgG fusion protein part 
by the open squares. 
Fig. 1A represents a schematic view of the t ransmembrane 
form of gp 130. The extracellular part consists of six f ibronectin 
type II I  modules, two of which form a cytokine receptor do- 
main (shown in black). To define the gp130 extracellular region 
responsible for binding the IL-6/IL-6R complex, we con- 
structed two deletion mutants  of the gpl30 protein and sub- 
cloned them into the expression vector pSVLgpl30. To avoid 
the necessity of using antibodies to precipitate the ternary com- 
plex that might interfere with the complex formation, the mu- 
tant proteins were expressed as soluble IgG fusion proteins. 
The fusion proteins can be precipitated with protein A-Sepha- 
rose via the IgG constant domain. The truncated gp 130 cDNAs 
were subcloned into the expression vector pSVLshgpl30- IgG 
containing a cDNA encoding the human soluble gp 130 with the 
constant domain of  human IgG1 fused to its C-terminus (Fig. 
1B). The first deletion mutant  shgpl30AF- IgG lacks the three 
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Fig. 2. Expression of shgpl30-IgG, shgpl30ACR-IgG and shgpl30AF 
in COS-7 cells. 10 7 COS-7 cells were transiently transfected with 30pg 
of pSVLshgpl30-IgG (lane 2), pSVLshgpl30ACR-IgG (lane 3) or 
pSVLshgp 130AF-IgG (lane 4) and metabolically abeled with [35S]cyste- 
ine/methionine. The 35S-labeled IgG fusion proteins were precipitated 
from supernatants (A) and cell lysates (B) with 1.25 mg/ml protein 
A-Sepharose via the IgG constant domain. The proteins, indicated by 
arrows, were visualized by SDS-PAGE and fluorography. Non-trans- 
fected cells (lane 1) are included as control. 
membrane proximal fibronectin type III modules (amino acids 
302 to 582). In a second mutant shgpl30ACR-IgG, the three 
N-terminal fibronectin type III modules of the gp 130 extracel- 
lular domain (amino acids 16 to 304) were deleted. This deletion 
includes the cytokine receptor domain composed of the second 
and the third fibronectin repeats [14] (see Fig. 1B). 
The pSVL expression vectors encoding shgp130-IgG as well 
as the deleted proteins hgpl30ACR-IgG and shgpl30AF-IgG 
were transiently transfected into COS-7 cells. To study their 
expression the IgG fusion proteins from supernatants and cell 
lysates of transfected COS-7 cells metabolically labeled with 
[35S]cysteine/methionine were precipitated with protein A- 
Sepharose and analysed by SDS-PAGE and fluorography (Fig. 
2). 
The shgpl30-IgG was expressed and secreted as a protein 
with a relative molecular weight of approximatly 120 kDa (Fig. 
2A, lane 2), both the secreted eletion mutants migrated at 
about 75 to 80 kDa (Fig. 2A, lanes 3 and 4). The corresponding 
proteins detected in the cell lysates (Fig. 2B, lanes 2 to 4) are 
of a somewhat lower apparent molecular mass than the secreted 
proteins, probably due to a non-terminally processed glycosyl- 
ation. It seems remarkable that although expressed at a high 
level, secretion of shgp 130ACR-IgG is very inefficient (Fig. 2A 
and 2B, lane 3). In contrast, the only weakly expressed 
shgpl30AF-IgG is exported into the medium to a larger extend 
(Fig. 2A and 2B, lane 4). This observation suggests that there 
might be a role for the N-terminal fibronectin domains in fold- 
ing or secretion of the gpl30 protein. 
In order to investigate the ability of the gpl30 deletion mu- 
tants to particpate in formation of the ternary IL-6/IL-6R/ 
gp130 complex, shgpl30-IgG, shgpl30ACR-IgG and 
shgp 130AF-IgG were expressed in COS-7 cells and precipitated 
from the supernatants with protein A-Sepharose. The Sepha- 
rose-bound gpl30 proteins were incubated with [35S]shIL-6R 
and human IL-6. The complexes were again sedimented, sepa- 
rated by SDS-PAGE and visualized by fluorography (Fig. 3). 
In lane 1 soluble [35S]IL-6R was immunoprecipitated with a 
specific anti-IL-6R antiserum in the presence of IL-6. As ex- 
pected, shIL-6R appears as a protein with a molecular mass of 
approximately 55 to 60 kDa. No radioactively abeled IL-6R 
was precipitated with IL-6 (lane 2) or without IL-6 (lane 3) in 
the absence of a specific antiserum (~-IL-6R). Lane 4 shows the 
co-precipitation f 35S-labeled IL-6R in a ternary complex with 
IL-6 and shgpl30-IgG. IL-6R co-precipitation did not occur 
when IL-6 was missing (lane 5). In lanes 6 and 7 shgpl30ACR- 
IgG and shgpl30AF-IgG were investigated. Only the addition 
of shgp 130AF-IgG led to co-precipitation f the IL-6R (lane 7) 
indicating that only the three N-terminal fibronectin type III 
modules, but not the three membrane proximal modules, are 
required for the formation of the ternary complex. 
In this first structure-function a alysis of the extracellular 
part of the signal-transducer gp130 we have demonstrated that 
the three membrane distal fibronectin type III modules of the 
gp130 protein including acytokine receptor domain are respon- 
sible for the formation of the ternary complex comprising IL-6 
and the soluble forms of IL-6R and gpl30. In analogy to the 
growth hormone receptor it can be hypothesized that the com- 
plex formation is brought about by the cytokine receptor do- 
main. 
Recently, it has been shown that OM binds directly to gpl30 
and behaves, at high doses, as an IL-6 antagonist [13]. It is 
interesting that apparently the same region of the gp 130 cytok- 
ine receptor domain interacts with OM, with LIF (after it has 
bound to the LIF receptor), with IL-6, CNTF and IL-11 after 
they have bound to their c~-receptors. For the growth hormone 
receptor two overlapping binding sites consisting of largely the 
same amino acids and with similar structures were identified to 
be essentiell for the recognition of two distinct sites on the 
growth hormone [18,19]. For the common fl-chain of the 
human GM-CSF, IL-3 and IL-5 receptors three amino acids 
were found to be involved in high affinity binding of GM-CSF 
and IL-5 but not of IL-3 [29]. Thus, we propose that different 
amino acids within the same region of the gp 130 cytokine recep- 
tor domain might function as binding determinants for the 
different cytokines/cytokine-c~-receptor complexes. 
As to be seen from Fig. 1A binding of the IL-6/IL-6R com- 
plex to the transmembrane gpl30 cytokine receptor domain 
raises a distance problem. The extracellular part of the IL-6R 
consists of only a membrane proximal cytokine receptor do- 
main and an N-terminal IgG-like domain. It is not clear to date 
how the cytokine receptor domains of IL-6R and gpl30 can 
simultaneously make contact with IL-6 being separated by 
three fibronectin modules. 
Further analysis of the membrane distal half of the gpl30 
protein should help to define more precisely where the contact 
with IL-6 and/or the IL-6R is made. In addition, it will be 
interesting to test whether a mutant of gpl30 containing only 
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Fig. 3. Formation of the ternary complex of IL-6, shIL-6R and 
shgpl30-IgG fusion proteins. Shgpl30-IgG fusion proteins were pre- 
cipitated from supernatants of transiently transfected COS-7 cells with 
protein A-Sepharose. Complex formation was conducted by incubation 
of IL-6 and [35S] labeled shIL-6R with the protein A-Sepharose bound 
gpl30 proteins. The IL-6/[35S]shIL-6R/shgp130-IgG complexes were 
sedimented by centrifugation, separated by SDS-PAGE and visualized 
by fluorography. ~-IL-6R, monospecific anti-human IL-6R antiserum. 
the cytokine receptor domain is capable of transducing an IL-6 
specific signal. 
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